Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatm...( BELGRADE SERBIA July 23 / Hard to Tre...),Health

BELGRADE, SERBIA, July 23 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).

The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.

In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.

The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.

The aforementioned report will be posted shortly on the HTDS corporate web site www.htdsmedical.com and on Pink Sheets under the tab "FILINGS" - Supplemental Information. http://www.pinksheets.com/pink/
'/>"/>